<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibodies associated with autoimmune encephalitis syndromes including paraneoplastic neurologic syndromes*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibodies associated with autoimmune encephalitis syndromes including paraneoplastic neurologic syndromes*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibodies associated with autoimmune encephalitis syndromes including paraneoplastic neurologic syndromes*</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="18%"></colgroup> <colgroup width="10%"></colgroup> <colgroup span="2" width="18%"></colgroup> <tbody> <tr> <td class="subtitle1">Antibody (alternative name)</td> <td class="subtitle1">Likely pathogenic mechanism</td> <td class="subtitle1">Neurologic phenotypes</td> <td class="subtitle1">Frequency of cancer (%)</td> <td class="subtitle1">Usual tumors</td> <td class="subtitle1">Sex, age-related, and other specificities</td> </tr> <tr> <td class="subtitle2_left" colspan="6">High-risk antibodies (&gt;70% associated with cancer)</td> </tr> <tr> <td class="indent1">Hu (ANNA-1)</td> <td>T cell-mediated</td> <td>Sensory neuronopathy, chronic gastrointestinal pseudo-obstruction, encephalomyelitis, limbic encephalitis</td> <td>85</td> <td>SCLC &gt;&gt; NSCLC, other neuroendocrine tumors, neuroblastoma</td> <td>Limbic encephalitis is usually nonparaneoplastic in patients &lt;18 years of age.</td> </tr> <tr> <td class="indent1">CV2/CRMP5</td> <td>T cell-mediated</td> <td>Encephalomyelitis, sensory neuronopathy</td> <td>&gt;80</td> <td>SCLC, thymoma</td> <td>Patients with an associated thymoma are younger and present more frequently with MG and less commonly with neuropathy.</td> </tr> <tr> <td class="indent1">SOX1</td> <td>Uncertain</td> <td>LEMS with and without rapidly progressive cerebellar syndrome</td> <td>&gt;90</td> <td>SCLC</td> <td>Stronger correlation with SCLC than with a particular neurologic presentation.</td> </tr> <tr> <td class="indent1">PCA-2 (MAP1B)</td> <td>T cell-mediated</td> <td>Sensorimotor neuropathy, rapidly progressive cerebellar syndrome, encephalomyelitis</td> <td>80</td> <td>SCLC, NSCLC, breast cancer</td> <td> </td> </tr> <tr> <td class="indent1">Amphiphysin</td> <td>Uncertain; possibly antibody-mediated</td> <td>Polyradiculopathy, sensory neuronopathy, encephalomyelitis, stiff-person syndrome</td> <td>80</td> <td>SCLC, breast cancer</td> <td>Associated antibodies commonly coexist. Patients with isolated antiamphiphysin are more likely to be females with breast cancer and stiff-person syndrome.</td> </tr> <tr> <td class="indent1">Ri (ANNA-2)</td> <td>T cell-mediated</td> <td>Brainstem/cerebellar syndrome, opsoclonus-myoclonus-ataxia syndrome</td> <td>&gt;70</td> <td>Breast &gt; lung (SCLC and NSCLC)</td> <td>Breast cancer in females; lung cancer in males.</td> </tr> <tr> <td class="indent1">Yo (PCA-1)</td> <td>T cell-mediated</td> <td>Rapidly progressive cerebellar syndrome</td> <td>&gt;90</td> <td>Ovarian cancer, breast cancer</td> <td>Almost all female; in males, antigen expression by tumor should be proven.</td> </tr> <tr> <td class="indent1">Ma2 and/or Ma</td> <td>T cell-mediated</td> <td>Limbic encephalitis, diencephalitis, brainstem encephalitis</td> <td>&gt;75</td> <td>Testicular cancer, NSCLC</td> <td>Young males: testicular tumors and isolated Ma2 positivity; older patients: SCLC and both Ma1/2 positivity.</td> </tr> <tr> <td class="indent1">Tr (DNER)</td> <td>Uncertain</td> <td>Rapidly progressive cerebellar syndrome</td> <td>90</td> <td>Hodgkin lymphoma</td> <td> </td> </tr> <tr> <td class="indent1">KLHL11</td> <td>T cell-mediated</td> <td>Brainstem/cerebellar syndrome</td> <td>80</td> <td>Testicular cancer</td> <td>Young males.</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Intermediate-risk antibodies (30 to 70% associated with cancer)</td> </tr> <tr> <td class="indent1">AMPAR</td> <td>Antibody-mediated</td> <td>Limbic encephalitis</td> <td>&gt;50</td> <td>SCLC, malignant thymoma</td> <td>Paraneoplastic origin is more likely when other onconeuronal antibodies co-occur.</td> </tr> <tr> <td class="indent1">GABA<sub>B</sub>R</td> <td>Antibody-mediated</td> <td>Limbic encephalitis</td> <td>&gt;50</td> <td>SCLC</td> <td>Paraneoplastic cases are more commonly observed in older males, in smokers, and in association with anti-KCTD16 antibodies. Most cases in young patients are not paraneoplastic.</td> </tr> <tr> <td class="indent1">mGluR5</td> <td>Antibody-mediated</td> <td>Encephalitis</td> <td>~50</td> <td>Hodgkin lymphoma</td> <td> </td> </tr> <tr> <td class="indent1">P/Q VGCC</td> <td>Antibody-mediated for LEMS; uncertain for cerebellar syndrome</td> <td>LEMS, rapidly progressive cerebellar syndrome</td> <td>50 (LEMS; nearly 90 for rapidly progressive cerebellar syndrome)</td> <td>SCLC</td> <td>Co-occurrence with N-type VGCC antibodies might be slightly more common in paraneoplastic LEMS.</td> </tr> <tr> <td class="indent1">NMDAR</td> <td>Antibody-mediated</td> <td>Anti-NMDAR encephalitis</td> <td>38</td> <td>Ovarian or extraovarian teratomas</td> <td>Tumor (mostly ovarian teratomas) predominates in females 25 to 45 years of age (50%). Older patients less frequently have tumors (&lt;25%), usually carcinomas. Paraneoplastic cases in children are very rare (&lt;10%).</td> </tr> <tr> <td class="indent1">Caspr2</td> <td>Antibody-mediated</td> <td>Morvan syndrome, limbic encephalitis, acquired neuromyotonia (Isaac syndrome)</td> <td> <p>50 (for Morvan syndrome)</p> &lt;30 (for all other syndromes)</td> <td>Malignant thymoma</td> <td>Caspr2 should be considered as an intermediate-risk antibody only in the setting of Morvan syndrome. When associated with other neurologic syndromes, the risk of cancer is very low.</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Lower-risk antibodies (&lt;30% associated with cancer)</td> </tr> <tr> <td class="indent1">mGluR1</td> <td>Antibody-mediated</td> <td>Cerebellar ataxia</td> <td>30</td> <td>Mostly hematologic</td> <td> </td> </tr> <tr> <td class="indent1">GABA<sub>A</sub>R</td> <td>Antibody-mediated</td> <td>Encephalitis</td> <td>&lt;30</td> <td>Malignant thymoma</td> <td>Paraneoplastic origin is less frequent in children (10%) than in adults (60%).</td> </tr> <tr> <td class="indent1">GFAP</td> <td>Uncertain</td> <td>Meningoencephalitis</td> <td>~20</td> <td>Ovarian teratomas, adenocarcinomas</td> <td>May occur as an immunologic accompaniment in anti-NMDAR encephalitis with ovarian teratomas.</td> </tr> <tr> <td class="indent1">GAD65</td> <td>Uncertain</td> <td>Limbic encephalitis, stiff-person syndrome, cerebellar ataxia</td> <td>&lt;15</td> <td>SCLC, other neuroendocrine tumors, malignant thymoma</td> <td>Paraneoplastic origin more likely in older patients, males, and in association with neuronal antibodies or atypical clinical presentations.</td> </tr> <tr> <td class="indent1">LGI1</td> <td>Antibody-mediated</td> <td>Limbic encephalitis</td> <td>&lt;10</td> <td>Malignant thymoma, neuroendocrine tumors</td> <td>Paraneoplastic cases are mainly observed in patients with Morvan syndrome and both serum LGI1 and Caspr2 antibodies.</td> </tr> <tr> <td class="indent1">DPPX</td> <td>Antibody-mediated</td> <td>Encephalitis with CNS hyperexcitability, PERM</td> <td>&lt;10</td> <td>B cell neoplasms</td> <td> </td> </tr> <tr> <td class="indent1">GlyR</td> <td>Antibody-mediated</td> <td>Limbic encephalitis, PERM</td> <td>&lt;10</td> <td>Malignant thymoma, Hodgkin lymphoma</td> <td> </td> </tr> <tr> <td class="indent1">AQP4</td> <td>Antibody-mediated</td> <td>Neuromyelitis optica spectrum disorder</td> <td>&lt;5</td> <td>Adenocarcinomas</td> <td>Paraneoplastic origin associated with older age, male sex, and severe nausea/vomiting at onset.</td> </tr> <tr> <td class="indent1">MOG</td> <td>Uncertain</td> <td>MOG antibody-associated disease</td> <td>5 cases reported</td> <td>Mostly ovarian teratomas</td> <td> </td> </tr> <tr> <td class="indent1">AK5</td> <td>T cell-mediated</td> <td>Limbic encephalitis</td> <td>&lt;1</td> <td> </td> <td>No known cancer association</td> </tr> <tr> <td class="indent1">GluK2</td> <td>Antibody-mediated</td> <td>Encephalitis with prominent cerebellar involvement</td> <td>&lt;1</td> <td> </td> <td>1 of 8 patients had a remote history of Hodgkin lymphoma</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ANNA: antineuronal nuclear antibody; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; CRMP5: collapsin-responsive mediator protein 5; MG: myasthenia gravis; SOX1: SRY-box transcription factor 1; LEMS: Lambert-Eaton myasthenic syndrome; PCA: Purkinje cell antibody; MAP1B: microtubule-associated protein 1B; DNER: delta/notch-like epidermal growth factor-related receptor; KLHL11: Kelch-like protein 11; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GABA<sub>B</sub>R: gamma-aminobutyric acid-B receptor; KCTD16: potassium channel tetramerization domain containing; mGluR5: metabotropic glutamate receptor 5; P/Q VGCC: P/Q type voltage-gated calcium channel; NMDAR: N-methyl-D-aspartate receptor; Caspr2: contactin-associated protein-like 2; mGluR1: metabotropic glutamate receptor 1; GABA<sub>A</sub>R: gamma-aminobutyric acid-A receptor; GFAP: glial fibrillary acidic protein; GAD: glutamic acid decarboxylase; LGI1: leucine-rich glioma inactivated protein 1; DPPX: dipeptidyl-peptidase-like protein; CNS: central nervous system; PERM: progressive encephalomyelitis with rigidity and myoclonus; GlyR: glycine receptor; AQP4: aquaporin 4; MOG: myelin oligodendrocyte glycoprotein; AK5: adenylate kinase 5; GluK2: glutamate kainate receptor subunit 2.</p>
* Antibodies to mGluR2 and SEZ6L2 are not listed as there is an insufficient number of cases to determine risk of cancer association.</div><div class="graphic_reference">Adapted from: Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8:e1014. Copyright © The Authors. Available at: <a href="https://nn.neurology.org/content/8/4/e1014.long" target="_blank">https://nn.neurology.org/content/8/4/e1014.long</a> (Accessed on March 28, 2022). Adapted under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 135170 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
